Buchumschlag

Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Taranika Sarkar Das, Kimberly Ho, Jahnavi Udaikumar, Bryan Chen, Olivia Delau, Aasma Shaukat, Ira Jacobson, Raiya Sarwar
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Hepatology Research
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis
von: Bettina Langhans, et al.
Veröffentlicht: (2024)

Validation of PBC‐10 in Japanese patients with primary biliary cholangitis
von: Akihito Takeuchi, et al.
Veröffentlicht: (2025)

Fibrosis stage is an independent predictor of liver‐related complications in primary biliary cholangitis
von: Yukihisa Fujinaga, et al.
Veröffentlicht: (2025)

Endoscopic management of primary sclerosing cholangitis
von: Suguru Mizuno, et al.
Veröffentlicht: (2025)

Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis
von: Marie Louise Næstholt Dahl, et al.
Veröffentlicht: (2025)

Effectiveness and safety of oral vancomycin in non‐primary sclerosing cholangitis paediatric inflammatory bowel disease
von: Silvana Ancona, et al.
Veröffentlicht: (2025)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
von: D. Bogatic, et al.
Veröffentlicht: (2024)

A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis
von: Manabu Hayashi, et al.
Veröffentlicht: (2024)

Association of Gastrointestinal Symptoms With Severity and Progression of Cognitive Impairment in Parkinson’s Disease: A Systematic Review and Meta‐Analysis
von: Kimberly Ho, et al.
Veröffentlicht: (2026)

Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
von: Keiji Tsuji, et al.
Veröffentlicht: (2025)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
von: Ayesha Shah, et al.
Veröffentlicht: (2024)

Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study
von: Marie‐Laura Godet, et al.
Veröffentlicht: (2025)

Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis
von: Gary Dezhi Zhang, et al.
Veröffentlicht: (2026)

STAT activation in regulatory CD4+ T cells of patients with primary sclerosing cholangitis
von: Leona Dold, et al.
Veröffentlicht: (2024)

Total astragalus saponins attenuate primary sclerosing cholangitis in mice by upregulation of TGR5
von: Qun Zhou, et al.
Veröffentlicht: (2024)

Caregiver‐reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis
von: Holly Payton Shifman, et al.
Veröffentlicht: (2024)

Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
von: John E. Eaton, et al.
Veröffentlicht: (2024)

Endoscopic retrograde cholangiopancreatography‐obtained bile culture in acute cholangitis: retrospective analysis of bile cultures and risk factors in a tertiary care center
von: Petros Stathopoulos, et al.
Veröffentlicht: (2024)

Prognostic significance of clinical scoring systems for large‐duct primary sclerosing cholangitis in Japanese patients
von: Koji Takahashi, et al.
Veröffentlicht: (2025)

Prognosis and clinicopathological features of patients with early‐onset and late‐onset colorectal cancer with second primary malignancies
von: Fan Chen, et al.
Veröffentlicht: (2024)

Endoscopic diagnosis of immunoglobulin G4‐related sclerosing cholangitis
von: Itaru Naitoh, et al.
Veröffentlicht: (2025)

Small bowel neuroendocrine tumors: Unique features and low lethality compared with small bowel adenocarcinoma
von: Zhen Yang, et al.
Veröffentlicht: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
von: Amanda Ricciuto, et al.
Veröffentlicht: (2024)

Reconsidering the microbial origins of primary sclerosing cholangitis and related autoimmune disorders: A case for the antro‐duodenal microbiome
von: Richard Kellermayer, et al.
Veröffentlicht: (2025)

Is there any association between celiac disease, myelodysplastic symdrome and primary sclerosing cholangitis?: A rare case report
von: Suaad Hamsho, et al.
Veröffentlicht: (2024)

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study
von: Rubén Terg
Veröffentlicht: (2008)

Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease
von: Alexis Bejcek, et al.
Veröffentlicht: (2024)

Systematic review and meta‐analysis: Impact of depression on prognosis in inflammatory bowel disease
von: Yuejin Ji, et al.
Veröffentlicht: (2024)

Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan
von: Sayumi Takahashi, et al.
Veröffentlicht: (2024)

Autoimmune cholangitis associated to IgG4 related sclerosing disease
von: Bernardo Frider
Veröffentlicht: (2011)

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
von: Palak J. Trivedi, et al.
Veröffentlicht: (2024)

Dominant stricture in paediatric‐onset primary sclerosing cholangitis is associated with impaired prognosis in a long‐term follow‐up
von: Andrea Tenca, et al.
Veröffentlicht: (2024)

The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta‐analysis
von: Dian‐yu Zheng, et al.
Veröffentlicht: (2024)

Gut microbiome‐targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta‐analysis
von: Tao Zhang, et al.
Veröffentlicht: (2024)

Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center
von: Chong‐Teik Lim, et al.
Veröffentlicht: (2024)

Forecasting the future prevalence of inflammatory bowel disease in Korea through 2048: an epidemiologic study employing autoregressive integrated moving average models
von: Ji Eun Kim, et al.
Veröffentlicht: (2024)

Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
von: Vineet Ahuja, et al.
Veröffentlicht: (2024)

Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence
von: Byung Wook Jung, et al.
Veröffentlicht: (2024)

Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance
von: David S Prince, et al.
Veröffentlicht: (2024)

A systematic review of the association between environmental risk factors and the development of irritable bowel syndrome
von: Qin Xiang Ng, et al.
Veröffentlicht: (2024)